Shares of VERONA PHARMA P/S (NASDAQ:VRNA) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $31.33.
Several research analysts have recently issued reports on the company. Zacks Investment Research downgraded VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Wedbush set a $56.00 price target on VERONA PHARMA P/S and gave the stock a “buy” rating in a research note on Thursday, December 27th. Finally, ValuEngine downgraded VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research note on Wednesday, December 5th.
VERONA PHARMA P/S stock opened at $10.00 on Friday. VERONA PHARMA P/S has a one year low of $8.60 and a one year high of $25.55. The firm has a market capitalization of $125.36 million, a price-to-earnings ratio of -4.15 and a beta of -0.37.
An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Foresite Capital Management IV LLC purchased a new stake in VERONA PHARMA P/S (NASDAQ:VRNA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,302 shares of the company’s stock, valued at approximately $104,000. VERONA PHARMA P/S accounts for 0.0% of Foresite Capital Management IV LLC’s holdings, making the stock its 21st biggest position. Foresite Capital Management IV LLC owned approximately 0.06% of VERONA PHARMA P/S at the end of the most recent quarter. Hedge funds and other institutional investors own 56.23% of the company’s stock.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.